Research Study

A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT03536559
Status 
Recruiting
Study Start/End 
Nov 9, 2020
Locations 
UBC Hospital
Name/Title 
MS Clinical Trial Research Coordinator
Phone 
604-822-1756
Email Address 
MS.NMO_Research@ubc.ca
Purpose of Study 

The purpose of this study is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable relapsing-remitting multiple
sclerosis (RMS).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.